Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study will offer a safe treatment for patients with relapsing recurring glioblastoma
(GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib
(Tarceva, OSI-774) can be safely used up to a dose of 150 mg two times a day for 12 months to
ultimately enhance survival of patients with relapsed/refractory GBM/AA. Correlation of
response to Tarceva with particular genetic alterations including epidermal growth factor
receptor variant type III (EGFRvIII) amplification and phosphatase and tensin homolog
(mutated in multiple advanced cancers 1) (PTEN) loss will be studied.